13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001608126
Total reported value
$2.8B
$2.8B
26 檔
41.0%
During the Q3 2024 filing period, Finepoint Capital LP (CIK: 0001608126) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $2.8B across 26 reported positions.
During Q3 2024, Finepoint Capital LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | QXO | Qxo Inc | Stock-Industrials | 29.51% | -2.60% | — | |
| 2 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 23.14% | +10.54% | — | |
| 3 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 17.10% | — | — | |
| 4 | LBRDK | Liberty Broadband-c | Stock-Comm Services | 11.20% | — | — | |
| 5 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.41% | — | +0.34% | |
| 6 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.14% | — | +0.74% | |
| 7 | ASND | Ascendis Pharma A/S | Stock-Other | 2.06% | — | +0.42% | |
| 8 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.81% | — | +0.31% | |
| 9 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 1.52% | — | +1.96% | |
| 10 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.42% | — | — | |
| 11 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.21% | — | +0.53% | |
| 12 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 1.17% | — | +2.76% | |
| 13 | ARVN | Arvinas Inc | Stock-Other | 1.03% | — | — | |
| 14 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 1.01% | — | — | |
| 15 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.98% | — | — | |
| 16 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.84% | — | +1.30% | |
| 17 | PRTA | Prothena Corporation plc | Stock-Other | 0.53% | — | — | |
| 18 | SLDB | Solid Biosciences Inc | Stock-Other | 0.49% | — | — | |
| 19 | EYPT | Eyepoint Inc | Stock-Other | 0.41% | — | — | |
| 20 | ✓ | Swiftmerge Acquisition CORP | Stock-Other | — | — | — | |
| 21 | ✓ | Compass Digital Acquisition Co | Stock-Other | — | — | — | |
| 22 | ✓ | Moneyhero Limited | Stock-Other | — | — | — | |
| 23 | ✓ | Marblegate Acquisition CORP | Stock-Other | — | — | — | |
| 24 | ✓ | Summit Healthcare Acquisition | Stock-Other | — | — | — | |
| 25 | ✓ | Calidi Biotherapeutics Inc | Stock-Other | — | — | — | |
| 26 | CLDWW | Calidi Biotherapeutics -cw23 | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Finepoint Capital LP reported a total U.S. public equity portfolio value of $2.8B across 26 disclosed positions in Q3 2024.
During Q3 2024, Finepoint Capital LP's top holdings by market value included QXO (29.5%)、SPY (23.1%)、IWM (17.1%). The largest single position, QXO, represented 29.5% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including QXO, SPY, IWM) accounted for 41.0% of total reported equity market value during Q3 2024.
In Q3 2024, Finepoint Capital LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.